-
1
-
-
33745632766
-
Pharmacokinetic/pharmacodynamic profile of voriconazole
-
DOI 10.2165/00003088-200645070-00002
-
Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663. (Pubitemid 43990568)
-
(2006)
Clinical Pharmacokinetics
, vol.45
, Issue.7
, pp. 649-663
-
-
Theuretzbacher, U.1
Ihle, F.2
Derendorf, H.3
-
3
-
-
39449117139
-
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
-
DOI 10.1086/524669
-
Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211. (Pubitemid 351269158)
-
(2008)
Clinical Infectious Diseases
, vol.46
, Issue.2
, pp. 201-211
-
-
Pascual, A.1
Calandra, T.2
Bolay, S.3
Buclin, T.4
Bille, J.5
Marchetti, O.6
-
4
-
-
0038282814
-
Voriconazole
-
DOI 10.1016/S0149-2918(03)80126-1
-
Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al. Voriconazole. Clin Ther. 2003;25:1321-1381. (Pubitemid 36677282)
-
(2003)
Clinical Therapeutics
, vol.25
, Issue.5
, pp. 1321-1381
-
-
Jeu, L.1
Piacenti, F.J.2
Lyakhovetskiy, A.G.3
Fung, H.B.4
-
5
-
-
0035991878
-
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
-
DOI 10.1128/AAC.46.8.2546-2553.2002
-
Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553. (Pubitemid 34793462)
-
(2002)
Antimicrobial Agents and Chemotherapy
, vol.46
, Issue.8
, pp. 2546-2553
-
-
Purkins, L.1
Wood, N.2
Ghahramani, P.3
Greenhalgh, K.4
Allen, M.J.5
Kleinermans, D.6
-
7
-
-
77952594210
-
Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) and voriconazole in patients with endstage renal failure during treatment with two hemodialysis systems and hemodiafiltration
-
Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) and voriconazole in patients with endstage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother. 2010;54:2596-2602.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 2596-2602
-
-
Hafner, V.1
Czock, D.2
Burhenne, J.3
-
8
-
-
33749639796
-
Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy
-
von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6:6.
-
(2006)
BMC Clin Pharmacol
, vol.6
, pp. 6
-
-
Von MacH, M.A.1
Burhenne, J.2
Weilemann, L.S.3
-
9
-
-
3543134887
-
Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
-
DOI 10.1093/jac/dkh310
-
Robatel C, Rusca M, Padoin C, et al. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother. 2004;54:269-270. (Pubitemid 39029007)
-
(2004)
Journal of Antimicrobial Chemotherapy
, vol.54
, Issue.1
, pp. 269-270
-
-
Robatel, C.1
Rusca, M.2
Padoin, C.3
Marchetti, O.4
Liaudet, L.5
Buclin, T.6
-
10
-
-
35448955384
-
Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration
-
DOI 10.1093/jac/dkm349
-
Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2007;60:1085-1090. (Pubitemid 47617758)
-
(2007)
Journal of Antimicrobial Chemotherapy
, vol.60
, Issue.5
, pp. 1085-1090
-
-
Fuhrmann, V.1
Schenk, P.2
Jaeger, W.3
Miksits, M.4
Kneidinger, N.5
Warszawska, J.6
Holzinger, U.7
Kitzberger, R.8
Thalhammer, F.9
-
11
-
-
38549162273
-
The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient
-
DOI 10.1097/FTD.0b013e31815c1672, PII 0000769120080200000020
-
Quintard H, Papy E, Massias L, et al. The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient. Ther Drug Monit. 2008;30:117-119. (Pubitemid 351161110)
-
(2008)
Therapeutic Drug Monitoring
, vol.30
, Issue.1
, pp. 117-119
-
-
Quintard, H.1
Papy, E.2
Massias, L.3
Lasocki, S.4
Arnaud, P.5
Desmonts, J.-M.6
Montravers, P.7
-
12
-
-
0030015661
-
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
-
DOI 10.1007/s001340050156
-
Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of theWorking Group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-710. (Pubitemid 26254283)
-
(1996)
Intensive Care Medicine
, vol.22
, Issue.7
, pp. 707-710
-
-
Vincent, J.-L.1
Moreno, R.2
Takala, J.3
Willatts, S.4
De Mendonca, A.5
Bruining, H.6
Reinhart, C.K.7
Suter, P.M.8
Thijs, L.G.9
-
13
-
-
0034815124
-
Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients
-
DOI 10.1034/j.1399-6576.2001.450802.x
-
Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45:929-934. (Pubitemid 32912336)
-
(2001)
Acta Anaesthesiologica Scandinavica
, vol.45
, Issue.8
, pp. 929-934
-
-
Bugge, J.F.1
-
14
-
-
35848960092
-
Drug dosing in continuous renal replacement therapy: General rules
-
DOI 10.1097/MCC.0b013e3282f0a3d3, PII 0007519820071200000004
-
Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007;13:645-651. (Pubitemid 350059527)
-
(2007)
Current Opinion in Critical Care
, vol.13
, Issue.6
, pp. 645-651
-
-
Schetz, M.1
-
15
-
-
69549119700
-
Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill
-
Kortgen A, Paxian M, Werth M, et al. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock. 2009;32: 358-365.
-
(2009)
Shock
, vol.32
, pp. 358-365
-
-
Kortgen, A.1
Paxian, M.2
Werth, M.3
-
16
-
-
69549131096
-
Acute liver injury and biomarkers: A biological lesson from indocyanine green
-
Krouzecky A, Radermacher P, Matejovic M. Acute liver injury and biomarkers: a biological lesson from indocyanine green. Shock. 2009;32: 340-341.
-
(2009)
Shock
, vol.32
, pp. 340-341
-
-
Krouzecky, A.1
Radermacher, P.2
Matejovic, M.3
-
17
-
-
34247558084
-
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
-
DOI 10.1016/j.bcp.2007.03.012, PII S0006295207001803
-
Murayama N, Imai N, Nakane T, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73:2020-2026. (Pubitemid 46677908)
-
(2007)
Biochemical Pharmacology
, vol.73
, Issue.12
, pp. 2020-2026
-
-
Murayama, N.1
Imai, N.2
Nakane, T.3
Shimizu, M.4
Yamazaki, H.5
-
18
-
-
77955154715
-
Review of the basic and clinical pharmacology of sulfobutylether-beta- cyclodextrin (SBECD)
-
Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99:3291-3301.
-
(2010)
J Pharm Sci
, vol.99
, pp. 3291-3301
-
-
Luke, D.R.1
Tomaszewski, K.2
Damle, B.3
|